| Literature DB >> 34557548 |
Jinjin Li1, Yuan Zhang2, Jingyun Zhang1, Rongna Dong1, Juanjuan Guo1, Qiumei Zhang1.
Abstract
AIMS: Few research was reported to explore oxidative stress in individuals with latent autoimmune diabetes in adults (LADA). Therefore, our goal is to study oxidative stress and related factors in LADA patients.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34557548 PMCID: PMC8455198 DOI: 10.1155/2021/5676363
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Clinical characteristics of study population during hospitalization.
| Parameter | LADA | Type 2 diabetes mellitus | Healthy volunteers | |
|---|---|---|---|---|
|
| 110 | 140 | 140 | |
| Male ( | 58 (52.7) | 64 (45.7) | 62 (44.3) | 0.10 |
| Age (year) | 44.7 ± 13.3 | 45.8 ± 6.8 | 45.9 ± 5.9 | 0.52 |
| BMI (kg/m2) | 21.4 ± 2.7 | 26.4 ± 3.5 | 21.3 ± 3.4 | ≤0.001 |
| SBP (mmHg) | 118.1 ± 12.9 | 132.0 ± 17.0 | 122.9 ± 20.5 | ≤0.001 |
| DBP (mmHg) | 72.4 ± 8.5 | 78.5 ± 8.5 | 73.3 ± 11.1 | ≤0.001 |
| HbA1c (mmol/mol) | 74 (17) | 76 (20) | 34 (16) | ≤0.001 |
| HbA1c (%) | 8.9 ± 1.64 | 9.1 ± 1.8 | 5.2 ± 1.5 | ≤0.001 |
| LDL-C (mmol/L) | 2.9 ± 0.7 | 3.4 ± 1.2 | 2.9 ± 0.9 | ≤0.001 |
| HDL-C (mmol/L) | 1.5 ± 0.7 | 1.4 ± 0.4 | 1.5 ± 0.2 | 0.02 |
| TG (mmol/L) | 1.3 ± 0.9 | 2.5 ± 1.0 | 1.3 ± 0.8 | ≤0.001 |
| 8-iso-PGF2 | 626.8 ± 94.2 | 678.2 ± 95.3 | 528.8 ± 80.9 | ≤0.001 |
| SOD (U/mL) | 110.9 ± 23.0 | 100.4 ± 24.0 | 130.7 ± 21.1 | ≤0.001 |
| Duration of diabetes (years) | 7.3 ± 4.3 | 7.1 ± 5.1 | — | 0.68 |
| Diabetic nephropathy ( | 17 (15.5) | 55 (39.3) | — | ≤0.001 |
| Peripheral neuropathy ( | 48 (43.6) | 65 (46.4) | — | 0.32 |
| Diabetic retinopathy ( | 37 (33.6) | 39 (27.9) | — | 0.42 |
| Diabetic ketosis ( | 40 (36.4) | 21 (15.1) | — | ≤0.001 |
| Macroangiopathy ( | 33 (30.0) | 44 (31.4) | — | 0.81 |
Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL-C: low-density lipoprotein-cholesterol; TG: total triglycerides; HDL-C: high-density lipoprotein-cholesterol; LADA: latent autoimmune diabetes in adults. ∗P values < 0.05 indicated statistical significance.
Figure 1Comparison of 8-iso-PGF2α and SOD levels in LADA, type 2 diabetes mellitus, and healthy volunteers. (a) Comparison of 8-iso-PGF2α levels in LADA, type 2 diabetes mellitus, and healthy volunteers. (b) Comparison of SOD levels in LADA, type 2 diabetes mellitus, and healthy volunteers. ∗∗P < 0.001.
Correlation analyses between 8-iso-PGF2α, SOD, and clinical characteristics in LADA patients.
| Parameter | 8-iso-PGF2 | SOD | ||
|---|---|---|---|---|
|
|
|
|
| |
| BMI (kg/m2) | 0.03 | 0.78 | -0.02 | 0.81 |
| SBP (mmHg) | 0.28 | ≤0.001 | -0.18 | 0.06 |
| DBP (mmHg) | 0.08 | 0.40 | -0.06 | 0.55 |
| HbA1c (%) | 0.59 | ≤0.001 | -0.42 | ≤0.001 |
| LDL-C (mmol/L) | 0.08 | 0.41 | -0.10 | 0.37 |
| HDL-C (mmol/L) | -0.03 | 0.78 | 0.01 | 0.95 |
| TG (mmol/L) | 0.05 | 0.10 | -0.11 | 0.27 |
| SOD (U/mL) | -0.73 | ≤0.001 | -0.73 | ≤0.001 |
| Duration (year) | 0.44 | ≤0.001 | -0.45 | ≤0.001 |
| Diabetic nephropathy | 0.35 | ≤0.001 | -0.32 | ≤0.001 |
| Peripheral neuropathy | 0.10 | 0.29 | -0.15 | 0.11 |
| Diabetic retinopathy | 0.43 | ≤0.001 | -0.44 | ≤0.001 |
| Diabetic ketosis | 0.25 | 0.01 | -0.26 | 0.01 |
| Macroangiopathy | 0.06 | 0.46 | -0.06 | 0.45 |
| Diabetic nephropathy | 0.35 | ≤0.001 | -0.32 | ≤0.001 |
Stepwise multiple regression analyses between clinical parameters and 8-iso-PGF2α, SOD in individuals with LADA.
| Parameter | Nonstandardized coefficient | Standard coefficient | |||
|---|---|---|---|---|---|
|
| Standard error | ||||
|
| |||||
| (constant) | 134.22 | 58.08 | 2.31 | 0.02 | |
| SBP (mmHg) | 1.11 | 0.44 | 0.15 | 2.51 | 0.01 |
| HbA1c (%) | 33.72 | 3.48 | 0.59 | 9.68 | ≤0.001 |
| Duration of illness (years) | 5.30 | 1.11 | 0.32 | 4.75 | ≤0.001 |
| Diabetic nephropathy | 44.97 | 18.43 | 0.17 | 2.43 | 0.02 |
| Diabetic retinopathy | 26.44 | 14.94 | 0.13 | 1.77 | 0.08 |
| Diabetic ketosis | 22.03 | 11.98 | 0.11 | 1.83 | 0.07 |
|
| |||||
| (constant) | 13.99 | 0.56 | 24.99 | ≤0.001 | |
| SBP (mmHg) | -0.13 | 0.30 | -0.04 | -0.45 | 0.66 |
| HbA1c (%) | -0.13 | 0.04 | -0.33 | -3.49 | ≤0.001 |
| HDL-C (mmol/L) | -0.49 | 0.64 | -0.08 | -0.77 | 0.44 |
| Diabetic retinopathy | -1.18 | 0.52 | -0.24 | -2.27 | 0.03 |
| Diabetic ketosis | -1.41 | 0.39 | -0.30 | -3.64 | ≤0.001 |
Changes in clinical characteristics during baseline and 6 months of follow-up in individuals with LADA.
| Parameter | Baseline | Follow-up | ||
|---|---|---|---|---|
| BMI (kg/m2) | 21.4 ± 2.7 | 21.5 ± 2.8 | 0.10 | 0.92 |
| SBP (mmHg) | 118.1 ± 12.9 | 117.9 ± 12.3 | 0.25 | 0.80 |
| DBP (mmHg) | 72.5 ± 8.5 | 72.1 ± 7.9 | 0.78 | 0.44 |
| LDL-C (mmol/L) | 2.9 ± 0.7 | 2.8 ± 0.6 | 1.32 | 0.19 |
| HDL-C (mmol/L) | 1.5 ± 0.7 | 1.5 ± 0.8 | 0.07 | 0.94 |
| TG (mmol/L) | 1.3 ± 0.9 | 1.3 ± 0.3 | 5.37 | ≤0.001 |
| HbA1c (mmol/mol) | 74 (17) | 62 (17) | 4.98 | ≤0.001 |
| HbA1c (%) | 8.9 ± 1.6 | 7.8 ± 1.6 | 4.98 | ≤0.001 |
| 8-iso-PGF2 | 626.8 ± 94.2 | 601.4 ± 75.0 | 2.21 | 0.02 |
| SOD (U/mL) | 110.9 ± 23.0 | 116.5 ± 40.2 | 2.12 | 0.04 |